European Pharmaceutical Review

OCTOBER 19, 2022

Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 23 April 2013.

Food and Drug Administration 96

Food and Drug Administration Pharmaceutical products Pharmaceutical FDA 96

European Pharmaceutical Review

FEBRUARY 1, 2024

For at least a decade from 2013 until recently, LDL lowering treatments were stuck on a paradigm of just putting people on statins and not getting LDL levels down to certain goals” CETP inhibitors have been around for a while, but they have unfortunately been unsuccessful in getting onto the market commercially. “For

Pharma 97

Pharma Patients Pharmaceutical Leads 97

European Pharmaceutical Review

DECEMBER 19, 2023

A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient. About 800 million humans are injected with vaccines every year” Most vaccines in use today are relatively cheap to make and are injected into patients with mass‑produced and inexpensive (five-cent) disposable syringes.

Distribution 111

Distribution Manufacturing Food Pharmaceutical 111

European Pharmaceutical Review

DECEMBER 23, 2024

16 This has led to a need to develop and introduce patient-centric specifications. 16,17 A patient-centric quality standard (PCQS) is defined as a set of patient-relevant attributes and their associated acceptance ranges to which a drug product should conform within the expected patient exposure range. 2 May 2022.

Safety 52

Safety Pharmaceutical Manufacturing Management 52